• Je něco špatně v tomto záznamu ?

Management of cardiac aspects in children with Noonan syndrome - results from a European clinical practice survey among paediatric cardiologists

CM. Wolf, M. Zenker, E. Burkitt-Wright, T. Edouard, S. García-Miñaúr, J. Lebl, G. Shaikh, M. Tartaglia, A. Verloes, I. Östman-Smith

. 2022 ; 65 (1) : 104372. [pub] 20211028

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22011465

BACKGROUND: The majority of children with Noonan syndrome (NS) or other diseases from the RASopathy spectrum suffer from congenital heart disease. This study aims to survey cardiac care of this patient cohort within Europe. METHODS: A cross-sectional exploratory survey assessing the treatment and management of patients with NS by paediatric endocrinologists, cardiologists and clinical geneticists was developed. This report details responses of 110 participating paediatric cardiologists from multiple countries. RESULTS: Most paediatric cardiologists responding to the questionnaire were associated with university hospitals, and most treated <10 patients/year with congenital heart disease associated with the NS spectrum. Molecular genetic testing for diagnosis confirmation was initiated by 81%. Half of the respondents reported that patients with NS and congenital heart disease typically present <1y of age, and that a large percentage of affected patients require interventions and pharmacotherapy early in life. A higher proportion of infant presentation and need for pharmacotherapy was reported by respondents from Germany and Sweden than from France and Spain (p = 0.031; p = 0.014; Fisher's exact test). Older age at first presentation was reported more from general hospitals and independent practices than from university hospitals (p = 0.031). The majority of NS patients were followed at specialist centres, but only 37% reported that their institution offered dedicated transition clinic to adult services. Very few NS patients with hypertrophic cardiomyopathy (HCM) were reported to carry implantable cardioverter defibrillators for sudden cardiac death prevention. Uncertainty was evident in regard to growth hormone treatment in patients with NS and co-existing HCM, where 13% considered it not a contra-indication, 24% stated they did not know, but 63% considered HCM either a possible (20%) or definite (15%) contraindication, or a cause for frequent monitoring (28%). Regarding adverse reactions for patients with NS on growth hormone therapy, 5/19 paediatric cardiology respondents reported a total of 12 adverse cardiac events. CONCLUSIONS: Congenital heart disease in patients with NS or other RASopathies is associated with significant morbidity during early life, and specialty centre care is appropriate. More research is needed regarding the use of growth hormone in patients with NS with congenital heart disease, and unmet medical needs have been identified.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22011465
003      
CZ-PrNML
005      
20220506130759.0
007      
ta
008      
220425s2022 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejmg.2021.104372 $2 doi
035    __
$a (PubMed)34757052
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Wolf, Cordula M $u Department of Congenital Heart Defects and Pediatric Cardiology, German Heart Center Munich, Technical University of Munich, Munich, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany
245    10
$a Management of cardiac aspects in children with Noonan syndrome - results from a European clinical practice survey among paediatric cardiologists / $c CM. Wolf, M. Zenker, E. Burkitt-Wright, T. Edouard, S. García-Miñaúr, J. Lebl, G. Shaikh, M. Tartaglia, A. Verloes, I. Östman-Smith
520    9_
$a BACKGROUND: The majority of children with Noonan syndrome (NS) or other diseases from the RASopathy spectrum suffer from congenital heart disease. This study aims to survey cardiac care of this patient cohort within Europe. METHODS: A cross-sectional exploratory survey assessing the treatment and management of patients with NS by paediatric endocrinologists, cardiologists and clinical geneticists was developed. This report details responses of 110 participating paediatric cardiologists from multiple countries. RESULTS: Most paediatric cardiologists responding to the questionnaire were associated with university hospitals, and most treated <10 patients/year with congenital heart disease associated with the NS spectrum. Molecular genetic testing for diagnosis confirmation was initiated by 81%. Half of the respondents reported that patients with NS and congenital heart disease typically present <1y of age, and that a large percentage of affected patients require interventions and pharmacotherapy early in life. A higher proportion of infant presentation and need for pharmacotherapy was reported by respondents from Germany and Sweden than from France and Spain (p = 0.031; p = 0.014; Fisher's exact test). Older age at first presentation was reported more from general hospitals and independent practices than from university hospitals (p = 0.031). The majority of NS patients were followed at specialist centres, but only 37% reported that their institution offered dedicated transition clinic to adult services. Very few NS patients with hypertrophic cardiomyopathy (HCM) were reported to carry implantable cardioverter defibrillators for sudden cardiac death prevention. Uncertainty was evident in regard to growth hormone treatment in patients with NS and co-existing HCM, where 13% considered it not a contra-indication, 24% stated they did not know, but 63% considered HCM either a possible (20%) or definite (15%) contraindication, or a cause for frequent monitoring (28%). Regarding adverse reactions for patients with NS on growth hormone therapy, 5/19 paediatric cardiology respondents reported a total of 12 adverse cardiac events. CONCLUSIONS: Congenital heart disease in patients with NS or other RASopathies is associated with significant morbidity during early life, and specialty centre care is appropriate. More research is needed regarding the use of growth hormone in patients with NS with congenital heart disease, and unmet medical needs have been identified.
650    _2
$a kardiologové $7 D000072096
650    _2
$a dítě $7 D002648
650    _2
$a genetické testování $7 D005820
650    12
$a vrozené srdeční vady $x diagnóza $x etiologie $x genetika $x terapie $7 D006330
650    _2
$a lidský růstový hormon $x terapeutické užití $7 D019382
650    _2
$a lidé $7 D006801
650    12
$a Noonanové syndrom $x komplikace $x diagnóza $x genetika $x terapie $7 D009634
650    12
$a lékařská praxe - způsoby provádění $7 D010818
650    _2
$a průzkumy a dotazníky $7 D011795
655    _2
$a časopisecké články $7 D016428
700    1_
$a Zenker, Martin $u Institute of Human Genetics, University Hospital Magdeburg, Magdeburg, Germany
700    1_
$a Burkitt-Wright, Emma $u Manchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust and University of Manchester, Manchester, UK
700    1_
$a Edouard, Thomas $u Endocrine, Bone Diseases, And Genetics Unit, Children's Hospital, Toulouse University Hospital, RESTORE INSERM UMR1301, Toulouse, France
700    1_
$a García-Miñaúr, Sixto $u Institute of Medical and Molecular Genetics (INGEMM), Hospital Universitario La Paz Research Institute (IdiPAZ), Hospital Universitario La Paz, Madrid, Spain
700    1_
$a Lebl, Jan $u Department of Pediatrics, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
700    1_
$a Shaikh, Guftar $u Department of Paediatric Endocrinology, Royal Hospital for Children, Glasgow, United Kingdom
700    1_
$a Tartaglia, Marco $u Genetics and Rare Diseases Research Division, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy
700    1_
$a Verloes, Alain $u Department of Genetics, APHP-Robert Debré University Hospital and Université de Paris Medical School, Paris, France
700    1_
$a Östman-Smith, Ingegerd $u Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden. Electronic address: ingegerd.ostman-smith@pediat.gu.se
773    0_
$w MED00166495 $t European journal of medical genetics $x 1878-0849 $g Roč. 65, č. 1 (2022), s. 104372
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34757052 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130752 $b ABA008
999    __
$a ok $b bmc $g 1789189 $s 1162663
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 65 $c 1 $d 104372 $e 20211028 $i 1878-0849 $m European journal of medical genetics $n Eur. J. med. genet. $x MED00166495
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Možnosti archivace